Pamidronic acid
- Generic Name
- Pamidronic acid
- Brand Names
- Pamisol
- Drug Type
- Small Molecule
- Chemical Formula
- C3H11NO7P2
- CAS Number
- 40391-99-9
- Unique Ingredient Identifier
- OYY3447OMC
- Background
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.
Pamidronic acid was granted FDA approval on 31 October 1991.
- Indication
Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: filgrastimBiological: recombinant interferon alfaProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 77
- Registration Number
- NCT00004088
- Locations
- 🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Prevention of Steroid-Induced Osteoporosis in Children
- Conditions
- Osteoporosis
- First Posted Date
- 2001-08-16
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Target Recruit Count
- 40
- Registration Number
- NCT00022841
- Locations
- 🇺🇸
Washington University Medical School-St. Louis Children's Hospital, St. Louis, Missouri, United States
Pamidronate to Treat Osteogenesis Imperfecta in Children
- First Posted Date
- 2000-06-07
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 34
- Registration Number
- NCT00005901
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.